Molecular characterization and antifungal susceptibility of Aspergillus spp. isolated from critically ill COVID-19 patients: implications for suspected COVID-19-associated pulmonary aspergillosis (CAPA) in a Brazilian tertiary referral hospital
Clicks: 26
ID: 328183
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
7.5
/100
26 views
25 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #100 of 176 articles by views in medical mycology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 176 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
COVID-19-associated pulmonary aspergillosis (CAPA) is a severe complication in critically ill patients, but species identification and antifungal resistance data from middle-income countries remain limited. We analyzed 17 Aspergillus isolates from respiratory specimens of 15 critically ill patients with COVID-19 in São Paulo State, Brazil, during 2020-2021. Patients were retrospectively classified according to ECMM/ISHAM criteria as probable CAPA (n = 5), possible CAPA (n = 7), or non-CAPA (n = 3). Complementary reassessment using the 2024 FUNDICU definitions classified patients as probable invasive pulmonary aspergillosis (IPA; n = 3), probable tracheobronchial aspergillosis (TBA; n = 1), or as not meeting these definitions (n = 9); two were ineligible due to classical EORTC/MSGERC host factors (n = 2). Species identification was performed by benA sequencing and MALDI-TOF MS. Susceptibility to amphotericin B (AMB), itraconazole (ITZ), voriconazole (VCZ), and posaconazole (PCZ) was determined according to CLSI M38-A2, and cyp51A and its promoter were analyzed in A. fumigatus. The predominant species were A. fumigatus (n = 7) and A. flavus (n = 5), followed by A. tamarii (n = 2), A. parasiticus, A. terreus, and A. welwitschiae (n = 1 each). All A. fumigatus isolates exhibited non-wild-type phenotypes (NWT) against PCZ, with some also showing reduced susceptibility to ITZ and AMB. Silent cyp51A mutations occurred in three A. fumigatus isolates, while several section Flavi isolates displayed multiazole NWT. These findings highlight diagnostic limitations and emerging azole resistance, supporting susceptibility testing and surveillance.
| Reference Key |
openalex_W7212085117
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Tiago Alexandre Cocio, Vivian Caso Coelho, Ludmilla Tonani, Ingrid Gonçalves Costa – Leite, Marcia Regina von Zeska Kress, Gilda Maria Bárbaro Del Negro, Márcia de Souza Carvalho Melhem, Célia Soares, Nelson Lima, Tânia Sueli de Andrade, Marcello Mihailenko Chaves Magri, Gil Benard, Roberto Martínez, Valdes Roberto Bóllela |
| Journal | medical mycology |
| Year | 2026 |
| DOI |
10.1093/mmy/myag092
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.